Comparison of hierarchical EMAX and NDLM models in dose-response for early phase clinical trials

BACKGROUND: Phase II clinical trials primarily aim to find the optimal dose and investigate the relationship between dose and efficacy relative to standard of care (control). Therefore, before moving forward to a phase III confirmatory trial, the most effective dose is needed to be identified. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Xiaqing, Gajewski, Byron J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7370408/
https://www.ncbi.nlm.nih.gov/pubmed/32690004
http://dx.doi.org/10.1186/s12874-020-01071-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7370408/
https://www.ncbi.nlm.nih.gov/pubmed/32690004
http://dx.doi.org/10.1186/s12874-020-01071-2

Ejemplares similares